Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival

Abd El-Rehim DM(2005)High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses Int J Cancer 116 340-350

Ball G(2009)Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 100 1806-1811

Pinder SE(2003)Molecular classification of breast carcinomas using tissue microarrays Diagn Mol Pathol 12 27-34

Rakha E(2006)Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index Clin Cancer Res 12 2468-2475

Paish C(2008)Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer BMC Cancer 8 153-22

Robertson JF(2006)HER2 testing in breast cancer: NCCN Task Force report and recommendations J Natl Compr Canc Netw 4 S1-1112

Macmillan D(2005)A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors Cancer Epidemiol Biomarkers Prev 14 1108-2688

Blamey RW(1999)Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers Clin Cancer Res 5 2682-178

Ellis IO(1992)Statistical validation of intermediate endpoints for chronic diseases Stat Med 11 167-779

Azzato EM(2005)Protein expression profiling identifies subclasses of breast cancer and predicts prognosis Cancer Res 65 767-1073

Abd El-Rehim DM(2005)High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses Int J Cancer 116 340-350

Ball G(2009)Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 100 1806-1811

Pinder SE(2003)Molecular classification of breast carcinomas using tissue microarrays Diagn Mol Pathol 12 27-34

Rakha E(2006)Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index Clin Cancer Res 12 2468-2475

Paish C(2008)Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer BMC Cancer 8 153-22

Robertson JF(2006)HER2 testing in breast cancer: NCCN Task Force report and recommendations J Natl Compr Canc Netw 4 S1-1112

Macmillan D(2005)A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors Cancer Epidemiol Biomarkers Prev 14 1108-2688

Blamey RW(1999)Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers Clin Cancer Res 5 2682-178

Ellis IO(1992)Statistical validation of intermediate endpoints for chronic diseases Stat Med 11 167-779

Azzato EM(2005)Protein expression profiling identifies subclasses of breast cancer and predicts prognosis Cancer Res 65 767-1073